Latest news with #MattScalo
Yahoo
29-07-2025
- Business
- Yahoo
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the second quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at following the call. About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit Investor Contact Matt Scalo (801) 584-3532 IR@ Media Contact Kate Schraml(224) 875-4493PR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025. Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025. Live and archived webcasts of all presentations can be viewed at About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit Investor Contact Matt Scalo (801) 584-3532 IR@ Media Contact Kate Schraml(224) 875-4493PR@ in to access your portfolio
Yahoo
14-05-2025
- Business
- Yahoo
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025. Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025. Live and archived webcasts of all presentations can be viewed at About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit Investor Contact Matt Scalo (801) 584-3532 IR@ Media Contact Kate Schraml(224) 875-4493PR@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
